Clínic Hospital
If you are the contact person for this centre and you wish to make any changes, please contact us.
Head of the Cardiology Department at the Hospital Clínic de Barcelona and researcher at the National Centre for Cardiovascular Research (CNIC) and at the August Pi Sunyer Biomedical Research Institute (IDIBAPS)
Psychiatrist and researcher at the Bipolar and Depressive Disorders Unit of the Hospital Clínic de Barcelona
Head of the Arrhythmias and Physical Activity research group at IDIBAPS, cardiac electrophysiologist at Hospital Clínic Barcelona, associate professor of Medicine at the University of Barcelona and researcher at CIBERCV.
Researcher of the Centre for Biomedical Research in Mental Health Network (CIBERSAM). Head of the Psychiatry and Psychology Department at the Hospital Clínic de Barcelona and lecturer at the University of Barcelona
Assistant Doctor of Psychiatry and postdoctoral researcher at the Bipolar and Depressive Disorders Unit of the Psychiatry and Psychology Department of the Hospital Clínic de Barcelona.
Professor of Medicine at the University of Barcelona and coordinator of the Central Sensitisation Unit at the Hospital Clínic de Barcelona.
Research Professor at IDIBAPS-Hospital Clínic de Barcelona and Scientific Director of CIBEREHD - Carlos III Health Institute
Head of the HIV-AIDS unit, Hospital Clínic-Barcelona
Endocrinologist at the Obesity Unit of the Endocrinology and Nutrition Service of the Hospital Clínic de Barcelona and former member of the Spanish Obesity Society (SEEDO).
Head of the Immunology Service
A few weeks ago, a press release from the Biogen and Eisai companies reported significant results from their lecanemab antibody for the treatment of early-stage Alzheimer's. The data from the phase 3 trial are now published in the New England Journal of Medicine, coinciding with the CTAD conference on Alzheimer's disease clinical trials in San Francisco. Data from the phase 3 clinical trial are now published in the New England Journal of Medicine, coinciding with the 15th CTAD Alzheimer's disease clinical trials conference in San Francisco.
A pioneering phase 1 clinical trial has tested a type of cancer immunotherapy. Researchers have modified patients' own T-lymphocyte receptors using the CRISPR tool to direct them against specific targets on their own tumours. The results are published in the journal Nature.
A phase 2 clinical trial has examined the use of the hallucinogen psilocybin in different amounts for the treatment of resistant depression. The results are published in the New England Journal of Medicine.
A Canadian study published in the Canadian Journal of Cardiology found that adjusted mortality from myocardial infarction is not different between men and women aged 18-55 years, but hospital readmission in the following year is higher in women.
Research among more than 7,000 US adults shows small changes in extraversion, agreeableness, openness to change and conscientiousness between the period before the covid-19 pandemic and the year 2022, especially in younger people. The study is published in PLOS ONE.
Psychological distress, including depression, anxiety, worry, perceived stress and loneliness, prior to covid-19 infection was associated with an increased risk of persistent covid, according to research published in JAMA Psychiatry.
US researchers have designed an intranasal vaccination device that is capable of delivering immunising proteins through the mucosal surface. The research, published in Science Translational Medicine, shows that strong antibody responses against viruses such as HIV and SARS-CoV-2 have been achieved in mice and non-human primates.
A study published today in the journal PLoS ONE examines the effectiveness of antidepressant treatments in improving patients' quality of life over time.
The director of the Vaccine Strategy of the European Medicines Agency (EMA), Marco Cavaleri, told a press conference on 11 January that "it is not sustainable in the long term to continue giving booster doses every three or four months [to the general population]". Spanish immunologists agree that this is not the right thing to do. In these reactions they explain why.
The first solid work on the ability of vaccines to stop infection with the omicron variant, which has just been published, reinforces the need for a third dose. Experts recall, however, that the aim of vaccines was never to stop infection, but to prevent severe disease. We summarize what is known so far about it.